Escolar Documentos
Profissional Documentos
Cultura Documentos
Schizophrenia
affecting about 7 per thousand of the adult population
mostly in the age group 15-35 years
the incidence is low (3-10,000), the prevalence is high due to
chronicity
about 24 million people wordwide
More than 50% of persons with schizophrenia are not
receiving appropriate care
90% of people with untreated schizophrenia are in developing
countries
Estimated %
70.31%
11.46%
9.99%
0.68%
1.50%
6.10%
Outpatient Use of Major Antipsychotic Drugs in Ambulatory Care Settings in the United
States, 1997-2000
3
,
50
Indications
Antipsychotic drugs
First generation
Second generation
Low-potency
Chlorpromazine (Taroctyl )
Thioridazine (Ridazin )
Midpotency
Trifluoperazine
Perphenazine (Perphenan )
Loxapine
Molindone
Highpotency
Haloperidol (Haldol )
Fluphenazine (Fludecate )
Thiothixene
aripiprazole
Antipsychotic Medications
10 and older for bipolar disorder, manic or mixed episodes;
13 to 17 for schizophrenia and bipolar;
chlorpromazine
clozapine
fluphenazine (generic only)
haloperidol
iloperidone
loxapine
molindone
olanzapine
paliperidone
perphenazine (generic only)
pimozide (for Tourette's syndrome)
quetiapine
risperidone
18 and older
18 and older
18 and older
3 and older
18 and older
18 and older
18 and older
18 and older; ages 13-17 as second line treatment
for manic or mixed episodes of bipolar disorder and
schizophrenia
18 and older
18 and older
12 and older
13 and older for schizophrenia;
18 and older for bipolar disorder;
10-17 for treatment of manic and mixed episodes of
bipolar disorder
13 and older for schizophrenia;
10 and older for bipolar mania and mixed episodes;
5 to 16 for irritability associated with autism
2 and older
18 and older
18 and older
18 and older NIMH
.1
CNS-PNS-
5 D1-D5
D2CNS-
( (clozapine
D4 , D2- ,
-
.2
, 5-HT2A
.3 , ,
cytochrome P-450 enzyme system-
PO 1-6
- (
sulpiride -) remoxipride-
extrapyramidal D2
100% ,
chlorpromazine
promethazine
pimozide Tourettes disorder-
risperidone
12
First generation
Extrapyramidal side effects
Metabolic disorders
Second generation
Metabolic disorders
Extrapyramidal side effects
13
.1 80%
.2 -
akathisia ,acute dystonia -
neuroleptic malignant ,parkinsonism -
syndrome
tardive dyskinesia
14
15
16
ACUTE PSYCHOSIS
Dosage Forms
1ST Episode
Chronic
MAINTENANCE
1ST Episode
Chronic
Lipids
Glucose
Chlorpromazine
O, S, IM
200-600
800400
150-600
250-750
+++
+++
++
Perphenazine
O, S, IM
12-50
24-48
12-48
24-60
/+
Trifluoperazine
O, S, IM
5-30
10-40
2.5-20
10-30
/+
Fluphenazine
O, S, IM
2.5-15
5-20
2.5-10
5-15
/+
/+
Fluphenazine
decanoate
Depot IM
Molindone
O, S
15-50
30-60
15-50
30-60
Loxapine
O, S, IM
15-50
30-60
15-50
30-60
Haloperidol
102.5
205
102.5
155
/+
17
20
23
24
ACUTE PSYCHOSIS
Dosage Forms 1ST Episode
Chronic
MAINTENANCE
1ST Episode
Chronic
Lipids
Glucose
2010
3015
2010
3015
/+
10
2010
10
2010
/+
600200
900400
600200
900300
++++
+++
+++
168
/+
/+
1224b
207.5
3010
157.5
3015
++++
+++
+++
96
126
93
156
/+
/+
/+
/+
Quetiapine
XR O
Risperidone
O, S, ODT
Sertindole
O
600200
900400
600200
900300
/+
42
63
62
83
/+
/+
164
2012
2012
3212
/+
Ziprasidone
O,
25IM
160120
200120
16080
200120
/+
NCEP:ATPIII 2001
Waist circumference
Central obesity:
Waist circumference >102 cm
(M), >88 cm (F)
Hypertriglyceridemia:
Triglycerides 150 mg/dL or
specific medication
Low HDL cholesterol:
<40 mg/dL and <50 mg/dL,
respectively, or specific
medication
Hypertension:
Blood pressure 130 mm
systolic or 85 mm diastolic or
specific medication
Fasting plasma glucose
100 mg/dL or previously
diagnosed Type 2 diabetes
Harrison's Principles of
Internal Medicine, 18e
26
Men
Women
Ethnicity
94 cm
80 cm
90 cm
80 cm
85 cm
90 cm
Japanese
Figure Legend:
95% Confidence IntervaIs for Weight Change After 10 Weeks on Standard Drug Doses, Estimated From a Random -Effects Model
Side effects
Weight gain/
28
sedation
Inactivity/obesity
29
30
31
32
33
34
35
36
37